BXTAccelyon (BXTA), the leading low dose rate (LDR) brachytherapy partner to hospitals and clinics worldwide, and distribution partner for the PrecisionPoint™ freehand prostate biopsy system, is pleased to announce its physical expansion into continental Europe, with the establishment of a new distribution warehouse and office in Holland.

Having previously serviced its clients from the United Kingdom, BXTA is investing in a Netherlands-based warehouse to minimise lead times for clients, ensuring its products are delivered even more quickly and efficiently. Following the United Kingdom’s withdrawal from the European Union, BXTAccelyon has also mitigated the risk of supply chain disruption arising from Brexit by deploying a hub on the continent.

This announcement follows the news earlier last year that the business appointed Wilco van der Lugt as Commercial Director for Europe as part of the strategic development of BXTA’s business expansion in Europe. Additional plans for 2021 include the addition of headcount to the region, under van der Lugt’s leadership, with the aim of growing a team across Europe.

Both investments in recruitment and physical presence represent the business’s commitment to building a strong infrastructure for mainland Europe, establishing its position as one of the leading providers of uro-oncology products and services.

Saheed Rashid, Managing Director, BXTAccelyon concludes: “As a business, we are committed to supporting healthcare professionals globally beat cancer, extend life, and create better quality outcomes. We are delighted with the receptiveness we’ve seen from our Dutch partners to date for both the PrecisionPoint Transperineal Access System and our low-dose-rate brachytherapy treatment and look forward to continuing this growth across mainland Europe for the improvement of prostate cancer outcomes.”